Cancer patients to continue promising treatments in major extension trial
NCT ID NCT07620574
First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 2 times
Summary
This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical benefit for people with cancers like kidney, liver, thyroid, and prostate cancer. Participants must have been deriving benefit in their prior study and have no access to the treatment locally.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cabozantinib, Zanzalintinib, Atezolizumab, Nivolumab, Abiraterone, Prednisone, Enzalutamide
- What this could lead to
- If successful, this study could allow patients with various cancers to continue benefiting from their treatment for a longer period, potentially improving long-term outcomes.
- What could go wrong
- This is an extension study, not a new treatment test, so it won't prove new cures. Side effects from long-term drug use remain possible, and only patients already benefiting are eligible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
May 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria). * Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator. * Able to comply with the long-term extension study protocol as determined by the investigator. * Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study. Key Exclusion Criteria: * Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study. * Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant. * Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study. * Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable). * Concurrent participation in any therapeutic clinical trial (other than the parent study). NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Greater Dayton Cancer Center
Kettering, Ohio, 45409, United States
-
New York Cancer and Blood Specialists
Bay Shore, New York, 11706, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping liver tumors to make them operable
- Gut bacteria may hold clues to dozens of diseases
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a gentler blood thinner shield cancer patients from new clots?
- Can a One-Week radiation course match four weeks for prostate cancer?